The prostate gland is about the size of a walnut at age 20. By 50, it’s typically closer to a golf ball. By 70, for many men, it’s a lemon. This growth — benign prostatic hyperplasia (BPH) — is not cancer, it’s not dangerous in itself, and it’s so common that many urologists consider it a normal part of male aging rather than a disease. But its effects on urinary and sexual function are significant, and understanding them allows men to make informed decisions about monitoring and treatment.
Beyond BPH, two other prostate conditions affect the majority of men who reach middle age: prostatitis (inflammation of the prostate, often without identifiable infection) and prostate cancer (the most common non-skin cancer in American men, with a 1-in-8 lifetime risk). Each condition, and each treatment, carries distinct implications for sexual function.
Benign Prostatic Hyperplasia (BPH)
What It Does
BPH enlarges the prostate gland, which surrounds the urethra (the tube that carries urine from the bladder). As the prostate enlarges, it compresses the urethra, producing lower urinary tract symptoms (LUTS): reduced urinary stream force, difficulty initiating urination, urgency, frequency, and nocturia (waking at night to urinate).
The sexual effects of BPH are substantial and often under-discussed:
Ejaculatory dysfunction. The prostate plays a central role in ejaculation — its muscular contractions propel semen into the urethra during orgasm. BPH affects this muscular function, producing changes in ejaculation force, volume, and sensation. Some men report reduced ejaculatory sensation or “weak” orgasms as an early BPH symptom.
Erectile dysfunction overlap. BPH and ED share many risk factors (age, cardiovascular disease, metabolic syndrome) and frequently co-occur. Additionally, the lower urinary tract symptoms themselves — disrupted sleep from nocturia, anxiety about urinary urgency — contribute to the psychological and physiological stress that impairs erectile function.
Sexual bother. Research using validated quality-of-life instruments consistently finds that men with BPH report significant sexual bother — the subjective sense that their sexual function has been affected — independently of their urinary symptom severity [1].
BPH Medications and Their Sexual Side Effects
The medications used to treat BPH have well-documented sexual side effects that physicians don’t always proactively discuss:
Alpha-blockers (tamsulosin, alfuzosin, silodosin): These relax the smooth muscle in the prostate and urethra, improving urinary flow. Tamsulosin and silodosin specifically are associated with retrograde ejaculation — orgasm occurs, but semen is propelled backward into the bladder rather than forward through the urethra. The orgasm often feels less intense; the man urinates cloudy urine afterward. Retrograde ejaculation is not harmful (the semen is later urinated out) but is a significant quality-of-life concern for many men, and it causes infertility. Alfuzosin has lower rates of ejaculatory side effects than tamsulosin or silodosin.
5-alpha reductase inhibitors (finasteride, dutasteride): These shrink the prostate by blocking conversion of testosterone to dihydrotestosterone (DHT). They’re highly effective for large prostates but carry persistent sexual side effects in a minority of men: reduced libido (in approximately 5-10%), reduced ejaculatory volume, and erectile dysfunction. More concerning, post-finasteride syndrome — a condition where sexual side effects persist after stopping the medication — has been reported, though its frequency and mechanism remain debated. These medications should be used after informed discussion of their sexual risk profile.
Combination therapy (alpha-blocker + 5-alpha reductase inhibitor): More effective for symptom relief but additive sexual side effects.
Prostatitis
Prostatitis — inflammation of the prostate — is the most common urological diagnosis in men under 50 and the third most common in men over 50. Chronic pelvic pain syndrome (CPPS), formerly called chronic nonbacterial prostatitis, is the most prevalent subtype and the most poorly understood.
How It Affects Sexual Function
CPPS produces pelvic pain that directly affects sexual function:
Pain during or after ejaculation. This is the most common sexual symptom. Pain can occur in the perineum, rectum, testes, or lower abdomen during or after orgasm, ranging from mild discomfort to severe cramping. For some men with CPPS, ejaculation is the primary trigger of pain flares, leading to avoidance of sexual activity.
Erectile dysfunction. Chronic pelvic pain activates the sympathetic nervous system and elevates cortisol — both of which impair erectile function. A significant proportion of men with CPPS develop secondary erectile dysfunction driven by pain anxiety and autonomic dysregulation.
Reduced sexual desire. Chronic pain is one of the most powerful suppressors of sexual desire. A man who associates sexual activity with pain anticipates pain, which activates the stress response, which suppresses desire before the encounter begins.
Treatment Implications for Sexual Function
Effective management of CPPS often improves sexual function by reducing the pain that drives avoidance and anxiety. Pelvic floor physical therapy — targeting the hypertonic (overly tense) pelvic floor muscles that contribute to CPPS — is one of the most evidence-supported treatments and directly addresses the muscular tension that impairs sexual function.
Prostate Cancer Treatment
Prostate cancer itself rarely causes sexual symptoms — in its early stages, it’s typically asymptomatic. The sexual effects are almost entirely treatment-related.
Radical Prostatectomy
Surgical removal of the prostate (radical prostatectomy) carries a high risk of erectile dysfunction due to potential damage to the cavernous nerves — nerve bundles that run alongside the prostate and are responsible for the penile erection reflex. Even with nerve-sparing surgical techniques, erectile dysfunction rates after prostatectomy are significant:
- With bilateral nerve-sparing surgery in an experienced surgeon’s hands: 40-60% of men recover erectile function within 2 years [2]
- Without nerve-sparing surgery: rates of permanent ED are considerably higher
Penile rehabilitation — a structured program of PDE5 inhibitor use, vacuum erection device therapy, and intracavernosal injections begun immediately after surgery — is recommended to maintain penile tissue oxygenation and minimize fibrosis while the nerves recover. The recovery window is typically 12-24 months; men who do not initiate rehabilitation early may develop permanent structural changes that limit the effectiveness of later treatment.
Retrograde ejaculation is universal after prostatectomy — the prostate is removed, so ejaculation is impossible. Orgasm remains possible but produces no emission. Urinary incontinence is a related post-surgical concern that affects sexual confidence independently of erectile function.
Radiation Therapy
External beam radiation and brachytherapy (implanted radioactive seeds) preserve erectile function better than surgery in the short term, but the radiation-induced vascular damage produces slowly progressive ED over years after treatment. By 5 years after radiation, ED rates approach those of surgery.
Androgen Deprivation Therapy (ADT)
ADT — chemical or surgical castration to suppress testosterone and slow prostate cancer growth — produces the most complete sexual dysfunction of any prostate cancer treatment. Testosterone near zero produces: complete loss of spontaneous libido, loss of erectile function, hot flashes, gynecomastia (breast tissue development), and significant psychological effects (depression, mood instability).
ADT is used for advanced or recurrent prostate cancer. When used intermittently (cycles of ADT with testosterone recovery periods), some sexual function may return during off-periods. Sexual rehabilitation during ADT — PDE5 inhibitors, vacuum erection devices, maintaining physical intimacy with a partner — helps preserve relationship quality and self-concept during treatment.
Talking to Your Doctor
Many men with prostate-related sexual symptoms never raise them with their physician because they assume sexual decline is an expected consequence they must accept. This assumption is frequently wrong — most prostate-related sexual symptoms have treatment options, and most physicians are willing to discuss them when asked directly.
Prepare for the conversation by documenting symptoms specifically:
- Exactly what has changed (erection quality, ejaculation, sensation, libido)
- When it started and whether it correlates with any medication change
- How much it’s affecting quality of life
- What you’ve already tried
The validated International Index of Erectile Function (IIEF) questionnaire is a free, five-minute self-assessment that provides standardized language for discussing erectile function changes with your physician — and gives the physician objective data to track change over time.
Key Takeaways
- BPH affects ejaculatory function and contributes to ED — often through sleep disruption, sexual bother, and shared vascular risk factors
- BPH medications have documented sexual side effects: alpha-blockers cause retrograde ejaculation; 5-alpha reductase inhibitors reduce libido and may cause persistent sexual dysfunction
- CPPS (chronic prostatitis) causes ejaculatory pain, ED, and reduced desire — pelvic floor physical therapy is an evidence-supported treatment
- Prostate cancer treatment produces significant sexual side effects that vary by treatment modality: surgery > radiation (for immediate ED), ADT produces near-complete sexual dysfunction
- Penile rehabilitation after prostatectomy — starting PDE5 inhibitors and vacuum devices early — significantly improves long-term erectile recovery
- Most prostate-related sexual symptoms have treatment options — don’t assume they must be accepted without medical discussion
Related Articles
- Men’s Sexual Health After 40: The Complete Guide
- How Erectile Function Changes After 40
- Talking to Your Doctor About Sexual Health
- Pelvic Floor Health for Men
References
McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. The Journal of Urology. 2011;185(5):1793-1803. PubMed
Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. European Urology. 2012;62(3):405-417. PubMed
Shoskes DA, Nickel JC, Dolinga R, et al. Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology. 2009;73(3):538-543. PubMed
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health routine.
